Galectin Therapeutics Inc. (GALT)
$3.69-4.65%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $243M
- Beta
- 0.38
- P/E (TTM)
- -8.64
- Short % float
- 19.62%
- Days to cover
- 33.7
- SI change
- -1.4%
- 1W
- -1.86%
- 1M
- -3.91%
- vs SPY 1W
- -1.72%
- vs SPY 1M
- -6.41%
Industry peers
FMP comparable companies · ranked by market cap
- DRTSSELLAlpha Tau Medical Ltd$1.3BBEARQ 15$14.25-3.65%
- LBRXSELLLB Pharmaceuticals Inc Common Stock$980MCRISISQ 75$34.16-3.17%
- DSGNSELLDesign Therapeutics, Inc.$730MCRISISQ -14$11.69-10.36%
- AURASELLAura Biosciences, Inc.$668MRECOVERYQ -6$6.46-4.13%
- IMABI-Mab$542M$2.88
- ALTSELLAltimmune, Inc.$517MCRISISQ -5$2.66-5.08%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on GALT?
- LOPJLB’s latest quantitative signal on Galectin Therapeutics Inc. (GALT) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is GALT in?
- Galectin Therapeutics Inc. (GALT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Galectin Therapeutics Inc. (GALT) do?
- Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergo…